Target intelligence / Profile preview

Beta-lactamase OXA-1 (OXA-1)

Target
OXA-1
Molecular classification
Enzyme, Hydrolase, Class D beta-lactamase, Serine beta-lactamase, Group 2d (Bush-Jacoby classification)
01

Overview

OXA-1 beta-lactamase is a molecular class D serine enzyme that plays a significant role in bacterial resistance to beta-lactam antibiotics. Primarily found in Gram-negative pathogens such as Escherichia coli and Klebsiella pneumoniae, it is characterized by its ability to hydrolyze penicillins, particularly oxacillin and cloxacillin, and its relative resistance to traditional inhibitors like clavulanic acid and tazobactam (1.4.2, 1.5.3). The enzyme utilizes a unique catalytic mechanism involving a carboxylated lysine residue in its active site to facilitate the hydrolysis of the beta-lactam ring (1.4.3). OXA-1 is frequently encoded on mobile genetic elements such as plasmids and class 1 integrons, which allows for its rapid spread across different bacterial species (1.4.4, 1.5.1). Clinically, its presence is often associated with the co-carriage of other resistance determinants, including extended-spectrum beta-lactamases (ESBLs) like CTX-M-15, leading to multi-drug resistant phenotypes that complicate the treatment of serious infections such as bacteremia and pneumonia (1.1.1, 1.3.4). While traditional inhibitors are often ineffective, newer agents like avibactam and experimental penem inhibitors show potential in neutralizing its activity (1.3.2, 1.3.3).

Other names
Class D beta-lactamaseOxacillinase-1OXA-30PenicillinaseOxacillin-hydrolyzing beta-lactamase 1
02

Mechanism of action

Inhibition of the enzyme's catalytic activity to prevent the hydrolysis of beta-lactam antibiotics, thereby restoring their antibacterial efficacy.

03

Biological functions

Antibiotic catabolic processHydrolysis of beta-lactam antibioticsConferring antimicrobial resistancePenicillin binding
04

Disease associations

InfectionAntimicrobial resistanceBacteremiaUrinary tract infectionSepticemia
05

Safety considerations

Therapeutic failure of standard beta-lactam/inhibitor combinationsRapid dissemination via plasmids and integronsCo-resistance to aminoglycosides and fluoroquinolonesLimited effectiveness of traditional inhibitors like clavulanic acid and tazobactam
06

Interacting drugs

Avibactam

11 more in the full profile.

07

Biomarkers

blaOXA-1 gene presenceReduced susceptibility to piperacillin-tazobactamOxacillin hydrolysis phenotype

Beyond the preview

Go deeper on Beta-lactamase OXA-1 (OXA-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-lactamase OXA-1 (OXA-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call